Conference Proceeding

Fucosylated Solid lipid nanoparticle of proteasome inhibitor for the treatment of temozolomide resistant Glioblastoma multiform

Mr. Pavan Kumar C.,
Department of Pharmacology, JSS College of Pharmacy, Ooty, Tamil Nadu, India

Mr. Pavan Kumar Chintamaneni obtained his Bachelors degree & Masters degree form Andhra University, Vishakapatnam, Andhra Pradesh. Later heworked as a assistant professor in Aditya Pharmacy College, suramplaem. Presently he is working as a research scholar in JSS College of pharmacy, Ooty, India.

Glioblastoma multiform (GBM) is a lethal cancer effecting 5-8 person per 100,000 and has devastating prognosis, it has no effective therapy till date due to the development of multidrug resistance (MDR) to conventional chemotherapeutic agents like temozolamide. Recent studies shown that bortezomib (BTZ) a boronic acid derivative is a protease inhibitor which is already in clinical use for myeloma has shown to induce apoptosis and arrest cell growth in stable GBM cells lines (T98G) as well as temozolomide resistant GBM cell lines (U251). However, the low Biography availability and off target effects of BTZ like peripheral neuropathy inspired us to formulate a site specific delivery system for BTZ. We have developed surface functionalized solid lipid nanoparticles (SLN) of BTZ for the specific targeting of MDR- GBM. The prepared SLN showed encapsulation efficiency of 82% and average particle size of 110 nm. Further fucosylation on the surface of prepared SLNs (f-SLNs) leads to increase of particle size to 140nm. The in vitro cytotoxicity and internalization in U251 cell lines were significantly improved with f-SLNs as compared to non-functionalized SLNs and naïve drug. Hence from this study we conclude that fucosylation on the surface of SLNs helps in overcoming the limitations associated with conventional therapeutics in treatment of MDR-GBM.

Published: 11 May 2017